Evidence map›Paper›PMID 42396254›Full record

ArticlePhysics and imaging in radiation oncology2026

Quantitative lung tissue functional analysis for pulmonary adverse event risk assessment prior to thoracic radiotherapy.

Sean R Miller, Daniel Polan, Chase Hadley, Karen Vineberg, Christina Lockhart, David N O'Dwyer, Wassim W Labaki, Craig J Galban, Steven G Allen, Martha Matuszak and 3 more

Abstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sean R MillerDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
Daniel PolanDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
Chase HadleyDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
Karen VinebergDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
Christina LockhartDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
David N O'DwyerDivision of Pulmonary & Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States of America.
Wassim W LabakiDivision of Pulmonary & Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States of America.
Craig J GalbanDepartment of Radiology, University of Michigan, Ann Arbor, MI, United States of America.
Steven G AllenDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
Martha MatuszakDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
Shruti JollyDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
Krithika SureshDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.
Charles K MatrosicDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Pulmonary adverse events are a limiting factor in thoracic radiotherapy and more common in patients with pulmonary comorbidities. Parametric response mapping (PRM) is an effective method of providing 3-dimensional underlying lung comorbidity data. We hypothesized that a commercial PRM software could identify patients at increased risk of pulmonary adverse events during radiotherapy. Materials and methods: Paired inspiratory/expiratory computed tomography (CT) scans obtained during simulation were processed using Lung Density Analysis (LDA) to classify lung tissue as Normal, Functional Low Density (FLD), Persistent Low Density (PLD), and Inspiration High Density (IHD). Patients were classified as elevated FLD, PLD, or IHD using predetermined thresholds. Multivariable models investigated associations between grade ≥ 2 pulmonary adverse events and (i) LDA measures, and (ii) clinical lung disease history. Model discrimination was assessed using area under the receiver operating characteristic curve (AUC). Results: Among 98 patients receiving definitive-intent thoracic radiotherapy, 22 experienced grade ≥ 2 pulmonary adverse events. Elevated IHD (Odds Ratio [OR] = 2.95; 95% Confidence Interval [CI]:1.12-7.97; Conclusion: Elevated IHD was a significant predictor of pulmonary adverse events, with PLD demonstrating a similar but nonsignificant trend. LDA measures demonstrated predictive performance comparable to clinical lung disease history, suggesting potential utility as a risk-screening tool pending validation in larger cohorts.

Indexed as

Lung function imagingParametric response mappingpulmonary toxicity

Identifiers

PMID42396254
PMCPMC13324496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.